Effects of benzalkonium chloride on growth and survival of Chang conjunctival cells

Investigative Ophthalmology and Visual Science

Volumn 40, Issue 3, 1999, Pages 619-630

  De Saint Jean, Magdalena ^a,c   Brignole, Françoise ^b   Bringuier, Anne France ^a   Bauchet, Alain ^c   Feldmann, Gerard ^a   Baudouin, Christophe ^c  

^a INSERM   (France)

^b Services d'Immunohématologie   (France)

^c HÔPITAL AMBROISE PARÉ   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BENZALKONIUM CHLORIDE; MONOCLONAL ANTIBODY;

ARTICLE; CELL GROWTH; CELL SURVIVAL; CELL VIABILITY; CONJUNCTIVA; CORNEA ENDOTHELIUM; CORNEA TRANSPLANTATION; CYTOLYSIS; DNA CONTENT; DRUG EFFECT; EPITHELIUM CELL; HUMAN; HUMAN CELL; LIPID MEMBRANE; MEDIATOR RELEASE; PRIORITY JOURNAL;

EID: 0032979565     PISSN: 01460404     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (83)

1. Green K, Chapman JM, Cheeks L, Clayton RM, Wilson M, Zehir A. Detergent penetration into young and adult rabbit eyes: comparative pharmacokinetics. J Toxicol Cut Ocul Toxicol. 1987;6:89-107.
2. Patarca R, Fletcher MA. Effects of benzalkonium salts on eukaryotic and microbial G-protein-mediated processes and surface membranes. Crit Rev Oncog. 1995;6:327-356.
3. Takahashi N, Fujikawa K, Miyakoshi M, Teraoka K, Taniuchi K. A flow cytometric study of the effects of benzalkonium chloride on the cell cycle. Nippon Ganka Gakkai Zasshi. 1992;96:823-827.
4. Damour O, Hua SZ, Lasne F, Villain P, Rousselle P, Collombel C. Cytotoxicity evaluation of antiseptics and antibiotics on cultured human fibroblasts and keratinocytes. Burns. 1992;18:479-485.
5. Eun H, Chung JH, Jung SY, Cho KH, Kim KH. A comparative study of the cytotoxicity of skin irritants on cultured human oral and skin keratinocytes. Br J Dermatol. 1994;130:24-28.
6. Willis CM, Stephens CJ, Wilkinson JD. Differential effects of structurally unrelated chemical irritants on the density and morphology of epidermal CD1+ cells. J Invest Dermatol. 1990;95:711-716.
7. Miszkiel KA, Beasley R, Rafferty P, Holgate ST. The contribution of histamine release to bronchoconstriction provoked by inhaled benzalkonium chloride in asthma. Br J Clin Pharmacol. 1988;25: 157-163.
8. Miszkiel KA, Beasley R, Holgate ST. The influence of ipratropium bromide and sodium chromoglycate on benzalkonium chloride-induced bronchoconstriction in asthma. Br J Clin Pharmacol. 1988;26:295-301.
9. van de Sandt JJM, Maas WJM, Doornink PC, Rutten AAJJL. Release of arachidonic and linoleic acid metabolites in skin organ cultures as characteristics of in vitro skin irritancy. Fundam Appl Toxicol. 1995;25:20-28.
10. Luster MI, Wilmer JL, Germolec DR, et al. Role of keratinocyte-derived cytokines in chemical toxicity. Toxicol Lett. 1995;82/83: 471-476.
11. Grant RL, Acosta D. Delayed toxicity of benzalkonium chloride and sodium dodecyl sulfate evaluated in primary cultures of rabbit corneal epithelial cells. Toxicol Methods. 1994;4:259-273.
12. Tripathi BJ, Tripathi RC, Kolli SP. Cytotoxicity of ophthalmic preservatives on human corneal epithelium. Lens Eye Toxicity Res. 1992;9:361-375.
13. Samples JR, Binder S, Nayak S. The effects of epinephrine and benzalkonium chloride on cultured corneal and trabecular mesh-work cells. Exp Eye Res. 1989;49:1-12.
14. Berdy GJ, Abelson MB, Smith LM, George MA. Preservative-free, artificial tear preparations: assessment of corneal epithelial toxic effects. Arch Ophthalmol. 1992;110:528-532.
15. Ichijima H, Petroll WM, Vester JV, Cavanagh HD. Confocal microscopic studies of living rabbit cornea treated with benzalkonium chloride. Cornea. 1992;11:221-225.
16. Imayasu M, Motiyama T, Ohashi J, Ichijima H, Cavanagh HD. A quantitative method for LDH. MDH and albumin levels in tears with ocular surface toxicity scored by Draize criteria in rabbit eyes. CLAO J. 1992;18:260-265.
17. Chou A, Hori S, Takase M. Ocular toxicity of beta-blockers and benzalkonium chloride in pigmented rabbits: electrophysiological and morphological studies. Jpn J Ophthalmol. 1985;29:13-23.
18. Becquet F, Goldschild M, Moldovan MS, Ettaiche M, Gastaud P, Baudouin C. Histopathological effects of topical ophthalmic preservatives on rat corneoconjunctival surface. Curr Eye Res. 1998; 17:419-425.
19. Mietz H, Niesen U, Krieglstein GK. The effects of preservatives and antiglaucomatous medication on histopathology of the conjunctiva. Graefes Arch Clin Exp Ophthalmol. 1994;232:561-565.
20. Fisher AA. Allergic contact dermatitis and conjunctivitis from benzalkonium chloride. Cutis. 1987;39:381-383.
21. Goh CL. Contact sensitivity to topical antimicrobials, II: sensitizing potentials of some topical antimicrobials. Contact Dermatitis. 1989;21:166-171.
22. Kuppens EV, de Jong CA, Stolwijk TR, de Kreizer RJ, van Best JA. Effects of timolol with and without preservative on the basal tear turnover in glaucoma. Br J Ophthalmol. 1995;79:339-342.
23. Gobbels M, Spitznas M. Corneal epithelial permeability of dry eyes before and after treatment with artificial tears. Ophthalmology. 1992;99:873-878.
24. Lemp MA, Zimmerman LE. Toxic endothelial degeneration in ocular surface disease treated with topical medications containing benzalkonium chloride. Am J Ophthalmol. 1988;105:670-673.
25. Baudouin C. Side effects of antiglaucomatous drugs on the ocular surface. Curr Opin Ophthalmol. 1996;7:80-86.
26. Yalvac IS, Gedikoglu G, Karagoz Y, et al. Effects of antiglaucoma drugs on ocular surface. Acta Ophthalmol Scand. 1995;73:246-248.
27. Broadway DC, Grierson I, O'Brien C, Hitchings RA. Adverse effects of topical antiglaucoma medication, II: the outcome of filtration surgery. Arch Ophthalmol. 1994;112:1446-1454.
28. Broadway D, Grierson I, Hitchings R. Adverse effects of topical antiglaucomatous medications on the conjunctiva. Br J Ophthalmol. 1993;77:590-596.
29. Young TL, Higginbotham EJ, Zou XL, Farber MD. Effects of topical glaucoma drugs on fistulized rabbit conjunctiva. Ophthalmology. 1990;97:1423-1427.
30. Kay JH, Calandra JC. Interpretation of eye irritation tests. J Soc Cos Chem. 1962;13:281-290.
31. Grant WM. Toxicology of the Eye. 3rd ed. Springfield, IL: Thomas; 1986:870-875.
32. Kennah HE II, Hignet S, Laux PE, Dorko JD, Barrow CS. An objective procedure for quantitating eye irritation based upon changes of corneal thickness. Fundam Appl Toxicol. 1989;12: 258-68.
33. Draize JH, Woodard G, Calvery HO. Methods for the study of irritation and toxicity of substances applied topically to the skin and mucous membranes. J Pharmacol Exp Ther. 1944;82:377-389.
34. de Silva O, Cottin M, Dami N, et al. Evaluation of eye irritation potential: statistical analysis and tier testing strategies. Food Chem Toxicol. 1997;35:159-164.
35. Cormier EM, Parker RD, Henson C, et al. Determination of the intra-and interlaboratory reproducibility of the low volume eye test and its statistical relationship to the Draize eye test. Regul Toxicol Pharmacol. 1996;23:156-161.
36. Grant RL, Acosta D. Prolonged adverse effects of benzalkonium chloride and sodium dodecyl sulfate in a primary culture system of rabbit corneal epithelial cells. Fundam Appl Toxicol. 1996;33:71-82.
37. Shaw AJ, Balls M, Clothier RH, Bateman ND. Predicting ocular irritancy and recovery from injury using Madin-Darby canine kidney cells. Toxicol In Vitro. 1991;5:169-174.
38. Yao C, Acosta D. Surfactant cytotoxicity potential evaluated with primary cultures of ocular tissues; a method for the culture of rabbit conjunctival epithelial cells and initial cytotoxicity studies. Toxicol Methods. 1992;2:199-218.
39. Takahashi N. Quantitative cytotoxicity of preservatives evaluated in cell culture with Chang's human conjunctival cells: effects of temperature on cytotoxicity. Jpn J Ophthalmol. 1982;26:234-238.
40. Takahashi N. A new method evaluating quantitative time-dependent cytotoxicity of ophthalmic solutions in cell culture: beta-adrenergic blocking agents. Graefes Arch Clin Exp Ophthalmol. 1983;220:264-267.
41. Lazarus HM, Imperia PS, Botti RE, Mack RJ, Lass JH. An in vitro methods which assesses corneal epithelial toxicity due to antineoplastic, preservative and antimicrobial agents. Lens Eye Toxic Res. 1989;6:59-85.
42. Takahashi N, Murayama T, Oda M, Miyakoshi M. Cell growth inhibition and DNA incorporation of mitomycin C in cell culture. Ophthalmic Res. 1998;30:120-125.
43. Murayama T, Takahashi N, Ikoma N. Cytotoxicity and characteristics of mitomycin C. Ophthalmic Res. 1996;28:153-159.
44. Ubels JL, Iorfino A, O'Brien WJ. Retinoic acid decreases the number of EGF receptors in corneal epithelium and Chang conjunctival cells. Exp Eye Res. 1991;52:763-765.
45. Schreiner J, Grabner G, Luger TA, Huber-Spitzy V, Haddad R, Stur M. Human corneal fibroblasts and a human conjunctival cell line (Chang) produce a thymocyte-activating factor (TAF) in vitro. Klin Monatsbl Augenheilkd. 1985;187:403-405.
46. Grabner G, Schreiner J, Luger TA, Stur M, Huber-Spitzy V. Corneal epithelial cells and human conjunctival cell line (Chang) produce an interleukin 3-like factor. Klin Monatsbl Augenheilkd. 1985;187: 406-407.
47. Nagata S, Goldstein P. The Fas death factor. Science. 1995;267: 1449-1456.
48. Suda T, Takahashi T, Goldstein P, Nagata S. Molecular cloning and expression of the Fas Ligand, a novel member of the tumor necrosis factor family. Cell. 1993;75:1169-1178.
49. Nagata S. Apoptosis by death factor. Cell. 1997;88:355-365.
50. Polyak K, Xia Y, Zweier JL, Kinzler KW, Vogelstein B. A model for p53-induced apoptosis. Nature. 1997;389:300-305.
51. Levine AJ. P53, the cellular gatekeeper for growth and division. Cell. 1997;88:323-331.
52. Zhang C, Ao Z, Seth A, Schlossmann SF. A mitochondrial membrane protein defined by a novel monoclonal antibody is preferentially detected in apoptotic cells. J Immunol. 1996;157:3980-3987.
53. Roth PA, Mikulka WR, Smith CU, Bolton WE, Zhang C, Schlossman S. A novel marker for measurement of apoptotic cells. Proceedings of XVIII Congress of the International Society for Analytical Cytology. Cytometry Suppl. 1996;8:44. Abstract CC17.
54. Toyoshima F, Moriguchi T, Nishida E. Fas induces cytoplasmic apoptotic responses and activation of the MKK7-JNK/SAPK and MKK6-p38 pathways independent of CPP32-like proteases. J Cell Biol. 1997;139:1005-1015.
55. Miyajima A, Nakashima J, Yoshioka K, Tachibana M, Tazaki H, Murai M. Role of reactive oxygen species in cis-dichlorodiammin-eplatinum-induced cytotoxicity on bladder cancer cells. Br J Cancer. 1997;76:206-210.
56. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods. 1983;65:55-63.
57. Sambroook J, Fritsch EF, Maniatis T. Molecular cloning. In: A Laboratory Manual. 2nd ed. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory; 1989;7:43-7.52 and 9.14-9.23.
58. Bonsing BA, Corver WE, Gorsira MCB, et al. Specificity of seven monoclonal antibodies against p53 evaluated with Western blotting, immunohistochemistry, confocal laser scanning microscopy, and flow cytometry. Cytometry. 1997;28:11-24.
59. Nicoletti I, Migliorati G, Pagliacci MC, Grignani F, Riccardi C. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Methods. 1991;139:271-279.
60. Certified cell lines-CCL. In: Hay R, Caputo J, Chen TR, Macy M, McClintock P, Reid Y, eds. ATCC: Cell Line and Hybridomas. Rockville, MD: American Type Culture Collection; 1994:15.
61. Baudouin C, De Saint Jean M, Brignole F, Goldschild M, Bourcier T, Goguel A. Expression of apoptotic and inflammatory markers in the human conjunctival epithelium [ARVO abstract]. Invest Ophthalmol Vis Sci. 1998;39(4):S551. Abstract nr 2541.
62. De Saint Jean M, Brignole F, Feldmann G, Baudouin C. Apoptosis and expression of inflammation-related proteins following IFN gamma treatment of epithelial conjunctival cells in vitro [ARVO Abstract]. Invest Ophthalmol Vis Sci. 1998;39(4):S548. Abstract nr 2527.
63. Brignole F, De Saint Jean M, Becquet F, Goldschild M, Goguel A, Baudouin C. Expression of Fas-Fas ligand antigens and apoptotic marker APO2.7 by the human conjunctival epithelium. Positive correlation with class II HLA DR expression in inflammatory conditions. Exp Eye Res. In press.
64. Li J, Eastman A. Apoptosis in an interleukin-2-dependent cytotoxic T lymphocyte cell line is associated with intracellular acidification. J Biol Chem. 1995;270:3203-3211.
65. Nicotera P, Bellomo G, Orrenius S. Calcium-mediated mechanisms in chemically induced cell death. Annu Rev Pharmacol Toxicol. 1992;32:449-470.
66. Wyllie AH. Glucocorticoid-induced thymocyte apoptosis is associated with endogenous endonuclease activation. Nature. 1980;284:555-556.
67. Tounecti O, Belehradek J, Mir LM. Relationships between DNA fragmentation, chromatin condensation, and changes in flow cytometry profiles detected during apoptosis. Exp Cell Res. 1995; 217:506-516.
68. 2+ pump present in reticulocyte endocytic vesicles. Biochem Mol Biol Int. 1995;35:889-898.
69. Cohen GM. Caspases: the executioners of apoptosis. Biochem J. 1997;326:1-16.
70. Lovely TJ, Levin DE, Klekowski E. Light-induced genetic toxicity of thiomerosal and benzalkonium chloride in commercial contact lens solutions. Mutat Res. 1982;101:11-18.
71. Dabrowska MI, Becks LL, Lelli JL, Levee MG, Hinshaw DB. Sulfur mustard induces apoptosis and necrosis in endothelial cells. Toxicol Appl Pharmacol. 1996;141:568-583.
72. Bustamante J, Dock L, Vahter M, Fowler B, Orrenius S. The semiconductor elements arsenic and indium induce apoptosis in rat thymocytes. Toxicology. 1997;118:129-136.
73. Albert ML, Sauter B, Bhardwaj N. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature. 1998;392:86-89.
74. Voll RE, Herrmann M, Roth EA, Stach C, Kalden JR. Immunosuppressive effects of apoptotic cells. Nature. 1997;390:350-351.
75. Ossina NK, Cannas A, Powers VC, et al. Interferon-γ modulates a p53-independent apoptotic pathway and apoptosis-related gene expression. J Biol Chem. 1997;272:16351-16357.
76. Wong GHW, Goeddel DV. Fas antigen and p55 TNF receptor signal apoptosis through distinct pathways. J Immunol. 1994;452:1751-1755.
77. Stern ME, Gao J, Brees DK. Mechanisms modulating apoptosis in the lacrimal gland of dry eye dogs [ARVO Abstract]. Invest Ophthalmol Vis Sci. 1997;38(4):S1155. Abstract nr 5393.
78. Tsubota K, Inoue H, Shimuta M, Saito I. Fas ligand-mediated exocrinopathy resembling Sjögren's syndrome in mice transgenic for IL-10 [ARVO Abstract]. Invest Ophthalmol Vis Sci. 1998;39(4): S1100. Abstract nr 5089.
79. Baudouin C, Brignole F, Becquet F, Pisella JP, Goguel A. Flow cytometry in impression cytology specimens: a new method for evaluation of conjunctival inflammation. Invest Ophthalmol Vis Sci. 1997;38:1458-1464.
80. Baudouin C, Haouat N, Brignole F, Bayle J, Gastaud P. Immunopathological findings in conjunctival cells using immunofluorescence staining of impression cytology specimens. Br J Ophthalmol. 1992;76:545-549.
81. Williams DE, Nguyen KD, Shapourifar-Tehrani S, Kitada S, Lee DA. Effects of timolol, betaxolol, and levobunolol on human tenon's fibroblasts in tissue culture. Invest Ophthalmol Vis Sci. 1992;33: 2233-2241.
82. Raynaud C, Laveran H, Rigal D, Bonicel P. Etude de la contamination bactérienne de collyres en usage clinique. J Fr Ophthalmol. 1997;20:17-24.
83. Schein OD, Hibberd PL, Starck T, Baker AS, Kenyon KR. Microbial contamination of in use ocular medications. Arch Ophtalmol. 1992;110:82-85.